The December 2026 X-NOVA2 MDD topline data readout is the next major catalyst; positive results could de-risk the psychiatry pipeline and offset concerns from the voluntary enrollment pause. Monitor for FDA acceptance of the NDA and any update on the MDD/BPD pause.
Drugs in focus
XENE drug pipeline →azetukalner
◆ Mixed Named in this 8-K- Impact
- Phase
- Filed/NDA under FDA review
- Time to market
- If the FDA accepts the NDA for filing (expected mid-November 2026), a standard 10-month review would set a PDUFA target action date around mid-2027. The drug could potentially launch in the second half of 2027 if approved.
- Next catalyst
- None dated
What to watchThe next near-term catalyst is the FDA's 60-day filing acceptance decision on the azetukalner NDA, expected around mid-November 2026. If accepted, a PDUFA date (likely standard review, ~10 months, pointing to mid-2027) would be set. The Q3 2026 earnings call on Nov 9 may also provide updates on the psychiatry program pause and the X-TOLE3/X-ACKT epilepsy trials. The psychiatry safety overhang and the stock's 46% decline from its 52-week high mean the FDA filing acceptance and any clarity on the depression program restart timeline are the key swing factors.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $41.39entry
- T+1 · 6d ago +1.72%α +0.40% · $42.10
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xenon reported Q3 2026 results with a net loss of $110.4M, wider than the $90.9M loss in Q3 2025, driven by higher R&D spending. The key catalyst is the NDA submission for azetukalner in focal seizures and the upcoming X-NOVA2 MDD topline data readout in December 2026, though a voluntary pause on new enrollment in MDD/BPD studies introduces uncertainty.
Key Financial Metrics
Key Facts
- NDA for azetukalner in focal seizures submitted to FDA in September 2026
- Phase 3 X-NOVA2 MDD study enrollment completed; topline data expected December 2026
- Voluntary pause on new patient enrollment in ongoing Phase 3 MDD and BPD studies announced in September 2026
- Positive Phase 1 data for XEN1701 (NaV1.7) and XEN1120 (KV7) pain programs; Phase 2 POC studies expected H1 2027
- Cash, cash equivalents and marketable securities of $1,153.5M as of September 30, 2026; cash runway into 2029
- Q3 2026 net loss of $110.4M vs $90.9M in Q3 2025; R&D expenses $95.6M vs $77.1M
- Net loss per share of $(1.11) for Q3 2026 vs $(1.15) in Q3 2025
Financial Impact
Q3 2026 net loss $110.4M, wider than $90.9M in Q3 2025; cash position $1.15B provides runway into 2029
Risk Factors
- Voluntary pause on new enrollment in Phase 3 MDD and BPD studies could signal undisclosed safety or efficacy concerns
- Pre-revenue biotech with widening net losses; no approved products or revenue stream
- NDA review outcome for azetukalner is uncertain; any FDA delays or rejections would be materially negative
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-453521 |
| Document: xene-20261109.htm | 0001193125-26-453521 |
| Document: 0001193125-26-453521-index-headers.html | 0001193125-26-453521 |
| Document: 0001193125-26-453521-index.html | 0001193125-26-453521 |
| Document: 0001193125-26-453521.txt | 0001193125-26-453521 |
| 8-K Data (Synthetic) | 0001193125-26-453521 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers